Md Jashim Uddin, Ph.D.

Md Jashim Uddin, Ph.D.

Associate Professor, Research, Department of Biochemistry

Md. Jashim Uddin received his B.S. (Honor’s) degree in 1991 in Chemistry and M.S. in 1993 in Organic Chemistry at Dhaka University, Bangladesh. In the year 1997, he was awarded the Japanese Government (Monbusho) scholarship for his doctoral study with Dr. Iwao Yamamoto in Japan and received the Ph.D. degree in Organic Chemistry at Shinshu University, Japan in 2001. It’s a constant challenge for organic chemists to control the stereoselectivity of the carbon-carbon or carbon-heteroatom bond forming reactions, where either a single or a group of chiral center originates in a single laboratory operation. In this regard, to control the stereoselectivity of the asymmetric cycloaddition reactions, he developed an isoxazolidine-based new chiral controller, which induced a high level of diastereoselectivity in intermolecular dipole-olefin cycloaddition reactions. This discovery is highly significant in modern asymmetric synthesis. 

In 2002, he was awarded the Alberta Heritage Foundation for Medical Research (AHFMR) scholarship for his postdoctoral training in medicinal chemistry to design COX-2 inhibitors with Dr. Edward Knaus at the University of Alberta, Canada, where he acquired an extensive structure-activity relationship study in selective COX-2 inhibition, from which a number of new drug design concepts, pertaining to COX-2 novel hitherto unknown pharmacophores, such as, azido and sulfonyl azido moieties, were developed. The acyclic (Z)- and (E)-olefinic COX-2 inhibitors that he designed are now at the leading edge of drug design worldwide. These olefinic biomolecules are being commercialized by Encapula NanoSciences LLC, Nashville, Tennessee, U.S.A. (http://www.encapsula.com). For further training in the area of medicinal and biological chemistry, he joined in a postdoctoral position at Marnett laboratory in October 2004. 

In July 2005, he was promoted to the faculty position and appointed as a Research Assistant Professor of Biochemistry, and later he was further promoted to a higher faculty rank and appointed as a Research Associate Professor of Biochemistry. Cyclooxygenase-2 (COX-2) catalyzes the committed step in the biosynthesis of prostaglandins, thromboxane, and prostacyclin. COX-2 is not expressed in most normal tissues but is present in inflammatory lesions and tumors. The expression of COX-2 appears to be an early event in tumorigenesis that plays a role in tumor progression. COX-2 mRNA and protein are detectable in a significant percentage of precursor lesions (e.g., colon polyps, Barrett’s esophagus) and an even higher percentage of malignant tumors (e.g., colon adenocarcinoma, esophageal adenocarcinoma). The other forms of cyclooxygenase, COX-1, does not appear to be elevated in tumors with the exception of ovarian carcinomas. Thus, COX-2 may be responsible for the significant increase in prostaglandin biosynthesis observed in many human tumors. COX-2 is the molecular target for the anti-inflammatory, analgesic, and antipyretic effects of non-steroidal anti-inflammatory drugs (NSAIDs) and for the COX-2-selective inhibitors, celecoxib and rofecoxib. NSAIDs exhibit varying selectivity for COX-2 and COX-1 but, in general, none of them displays high selectivity for COX-2. 

NSAIDs and COX-2-selective inhibitors possess cancer chemopreventive activity, retard the growth of human tumor xenografts in nude mice, and induce polyp regression in individuals with familial polyposis. These activities have been attributed to their ability to inhibit COX-2. The elevated expression of COX-2 in benign and malignant tumors and the apparent functional role that the enzyme plays in tumor growth suggests that COX-2 is an attractive target for the development of tumor-selective imaging agents. Our laboratory has developed a novel approach that allows the facile conversion of non-selective NSAIDs into highly selective COX-2 inhibitors. This is accomplished by conversion of the carboxylic acid functional group, common to most NSAIDs, to an amide or ester. Extensive structure-activity studies indicate that a diverse range of functional groups can be tethered to an NSAID through a stable amide linkage with retention of potency and selectivity for COX-2 inhibition. Indeed, it is extremely rare that the specific binding of an enzyme inhibitor allows such a wide range of structural flexibility. Dr. Uddin is interested in developing fluorescent or radiolabeled COX-2-targeted agents that selectively label COX-2 expressing tumor cells in vitro and in vivo. COX-2-selective imaging agents can be developed specifically for use with the optical modalities, near infrared (NIR) fluoresecence and two-photon microscopy, and the radiologic modalities, SPECT and PET, and that these agents can be used to monitor COX-2 expression during tumor initiation and progression.

These imaging approaches lead to determining the predictive value of COX-2 expression on the response to therapy, the effects of therapy on COX-2 expression, and the usefulness of imaging to design therapy based on COX-2 inhibition. The results of these experiments will form the framework for the rapid development of COX-2-targeted imaging agents for the clinical cancer detection in the early stage.

 

MEDIA COVERAGE

1. ‘Lit up COX-2 cancer probe’. VUMC Reporter Jun 12, Page 2, 2015.

2. ‘Challenge’ puts technology transfer ingenuity on display. VUMC Reporter Apr 17, Page 6, 2015.

3. Molecular imaging of inflammation and carcinogenesis. Cancer Prevention Research 4, 1523, 2011

4. Imaging agents offer new views of inflammation, cancer. Science Daily Oct 7, 2011.

5. New views of inflammation and cancer. VUMC Reporter Oct 21, Page 2, 2011.

6. Imaging of inflammation and cancer. Cancer Research. 70, 3418, 2010

7. Fluorescent agents target enzyme in cancer Cells. Chemical and Engineering News 88(7), 12, 2010.

8. Novel imaging agents shine light on developing tumors. VUMC Reporter May 7, Page 1, 2010.

9. Fluorescent compounds make tumor glow, cancer. Science Daily April 29, 2010.

10. Fluorescent inhibitors hold promise for early-stage tumor detection. Medical News April 29, 2010.                                                                            

 

AWARDS, HONORS AND RESEARCH GRANTS

American NCI/NIH – Research Grant Award #CA182850-01A1        

Role: Co-Investigator                                         

Grant Title– Detection of COX-2-expressed cancers by Fluorocoxib A

American NCI/NIH - VICMIC Pilot Grant Award #CA128323-4,5        

Role: Principal Investigator (PI)                            

Grant Title–Detection of COX-2 Expressing Canine Tumors by Optical Imaging Agent Fluorocoxib A.             

Canadian AHFMR – Postdoctoral Fellowship Award             

Role: Postdoctoral Investigator                            

Grant Title–Design, synthesis, biological and computational evaluation of COX-2 inhibitors. 

Japanese Government MONBUSHO – Graduate Scholarship Award     

Role: Ph.D. Student                                    

Grant Title–Stereoselective synthesis of chiral heterocycles from asymmetric 1,3-dipolar cycloaddition reactions. 

 

ACHIEVEMENTS HIGHLIGHTS

1. Fluorocoxib A (Xenolight®RediJect COX-2 Probe): Fluorocoxib A, the first COX-2-targeted optical imaging, is discovered. Fluorocoxib A is licensed to Perkin Elmer Company, USA, for commercialization for pre-clinical detection of inflammation and cancer. 

2. Certificate of Recognition: A ‘certificate of recognition’ is obtained for OMICS Scientific Community for extraordinary scientific contributions in COX-2 targeted delivery of imaging agents.

3. Perspective on Uddin, MJ et. al.: A perspective was published by scientific community recognizing Uddin’s contribution to the biomedical imaging field.

       

REVIEWER OF SCIENTIFIC JOURNALS

Journal of Medicinal Chemistry, 2005 – present

Bioorganic and Medicinal Chemistry, 2005 – present

Bioorganic and Medicinal Chemistry Letters, 2005 – present

Journal of Heterocyclic Chemistry, 2005 – present

European Journal of Medicinal Chemistry, 2005 – present

 

REVIEWER – RESEARCH GRANT

Multidisciplinary Research Grant, North Carolina Biotechnology Center - 2005

 

DISSERTATIONS

1. Ph.D.: Organic Chemistry. Synthesis and Structure of Chiral Heterobicycles and Their Application in Asymmetric Synthesis. Professor Iwao Yamamoto, Advisor.

2. M.S.: Organic Chemistry. Studies on Reactions of Substituted Chacones with Acyclic 1,3-Diketones. Professor M. G. Ahmed, Advisor.

 

SCIENTIFIC COMMUNITY SERVICES

Chair of Executive Committee: Network for Translational Research (NTR) Chemistry Core, National Institutes of Health (NIH), National Cancer Institute (NCI), USA, 2012—2013

 

BOOK CHAPTERS

1. Aldrich, M. B., Rasmussen, J. C., Azhdarinia, A., Joshi, B., Uddin, M. J., Akers, W. J., Culver, J. P., Smith, A., Bouchard, J-P., Kurabayashi, K. Translational Research in Biophotonics, 2013, Chapter 3, Page 29-67; National Cancer Institute, eBooks DOI: 10.1117/3.1002515.ch3; SPIE PRESS, Bellingham, Washington USA,  

 

PATENTS

1. Methods and compositions for diagnostic and therapeutic targeting of COX-2 (#US 2010/0254910)
June 2010

The disclosed subject matter provides compositions that selectively bind cyclooxygenase-2 and comprise a therapeutic and/or diagnostic moiety. Also, provided are methods for using the disclosed compositions for diagnosing (i.e. by imaging) a target cell and/or treating a disorder associated with a cyclooxygenase-2 biological activities.

2. Fluorocoxib A loading into ROS-responsive nano-particles (#US 62/191367)
February 2015

Disclosed are compositions and methods for making and using the disclosed compositions. In a further aspect, disclosed are compositions that comprise a cyclooxygenase-2-selective therapeutic and/or diagnostic agent having a therapeutic and/or diagnostic agent conjugated to a NSAID drug; and a ROS-responsive nanoparticle.

3. Composition and method for detecting hypoxia(#US 62/156055)
November 2015

Disclosed subject matter comprised diagnostic agent conjugated to a hypoxia marker moiety. Disclosed methods and compositions for diagnosing (i.e. by optical imaging) hypoxic cells and/or treating a disorder associated with hypoxia.

 

Ph.D. STUDENT SUPERVISED/MENTORED

Paola Malerba – Design, synthesis and in vivo evaluation of COX inhibitors also as novel specific PET imaging agents in cancer and inflammation models – Ph.D. Dissertation 2013

Vanderbilt University, USA, and University of Bari, Aldo Moro, Italy

 

SCIENTIFIC PUBLICATIONS

Click Here To Search For Uddin Articles on PubMed

 

2016

41. Bluett, R., Baldi, R., Haymer, A., Hartley, N., Marcus, D., Bey, R. M., Shonesy, B., Uddin, M. J., Lawrence J. Marnett, L. J., Colbran, R., Winder, D. Patel, S. An endocannabinoid mechanism promoting resilience to traumatic stress. Nature Neuroscience, Submitted 

40. Uddin, M. J., Crews, B. C., Xu, S., Ghebreselasie, K., Daniel, C.K., Kingsley, P. J., and Marnett, L.J. Antitumor activity of cytotoxic cyclooxygenase-2 inhibitors. ACS Chemical Biology, In Press 

39. Uddin, M. J.,* Moore, C. E., Crews, B. C., Daniel, C. K., Ghebreselasie, K., McIntyre, J. O., Marnett, L. J., and Jayagopal, A., Fluorocoxib A Enables Targeted Detection of Cyclooxygenase-2 in Laser–Induced Choroidal Neovascularization, Journal of Biomedical Optics, 2016, 21(9), 90503. (*Corresponding Author). See Reporter Article

38. Adeniji, A., Uddin, M. J., Zang, T., Tamae, D., Wangtrakuldee, P., Marnett, L. J., Penning, T. M., Discovery of (R)-2-(6-methoxynaphthalen-2-yl)butanoic acid As a Potent and Selective AKR1C3 Inhibitor. Journal of Medicinal Chemistry, 2016, 59(16), 7431-7444.

37. Foster, D.J., Wilson, J.M., Remke, D.H., Mahmood, M.S., Uddin, M.J., Wess, J., Patel, S., Marnett, L.J., Niswender, C.M., Jones, C.K., Xing, Z., Lindsley, C.W., Rook, J.M., Conn, P.J. Antipsychotic-like effects of M4 positive allosteric modulators are mediated by CB2 receptor-dependent inhibition of dopamine release. Neuron, 2016, 91(6), 1244-1252. 

36. Uddin, M. I., Evans, S. M., Craft, J. R., Capozzi,M. E., McCollum, G. W., Rong Yang, R., Lawrence J. Marnett, L. J., Uddin, M. J., Ashwath Jayagopal, A., and Penn, J. S. In Vivo Imaging of Retinal Hypoxia in a Model of Oxygen Induced Retinopathy. Scientific Reports, 6, 31011; doi: 10.1038/srep31011 (2016) 

35. Uddin, M. J., Werfel, T. A., Crews, B. C., Gupta, M. K., Marnett, L. J., Duvall, C. L. Fluorocoxib A loaded into ROS-responsive nanoparticles enables in vivo targeted visualization of cyclooxygenase-2 in inflammation and cancer. Biomaterials, 2016, 92, 71-80.

 

2015

34. Uddin, M. J.,* Crews, B. C., Ghebreselasie, K., Daniel, C. K., Kingsley, P. J., Xu, S., Marnett, L. J. Targeted delayed imaging of cancer by fluoroocoxib C, a near-infrared cyclooxygenase-2 probe. Journal of Biomedical Optics, 2015, 20(5), 050502 (*Corresponding Author).

33. Wilson, A. J., Fadare, O., Beeghly-Fadeil, A., Son, D-S., Liu, Q., Zhao, S., Saskowski, J., Uddin, M. J., Daniel, C., Crews, B. C., Lehmann, B. D., Pietenpol, J., Crispens, M. A., Marnett, L. J., Khabele, D. Genetic disruption of COX-1 inhibits multiple oncogenic pathways in high-grade serous ovarian cancer. Oncotarget, 2015, 6(25), 21353-21368.

32.  Ra, H., González-González, E., Uddin, M. J., King, B. L., Lee, A., Ali-Khan, I., Marnett, L. J., Tang, J., and Contag, C. H. Detection of non-melanoma skin cancer by in vivo fluorescence imaging with fluroocoxib. A. Neoplasia, 2015, 17(2), 201-207.

31. Uddin, M. I., Evans, S. M., Craft, J. R., Marnett, L. J., Uddin, M. J.* Joyagopal, A*. Applications of azo-based probes for imaging retinal hypoxia. ACS Medicinal Chemistry Letters, 2015, 6 (4), 445–449 (*Corresponding Author)

 

2014

30.  Uddin, M. J., Elleman, A. V., Ghebreselasie,K., Daniel, C.K., Crews,B. C., Nance, K. D.,  Huda, T., Rouzer, C. A., and Marnett,L.J. Design of fluorine-containing 3,4-diaryl-2(5H)-ones as selective COX-1 inhibitors. ACS Medicinal Chemistry Letters, 2014, 5, 1254-1258

29. Uddin, M. J.,* Crews,B.C., Huda, I., Ghebreselasie,K., Daniel, C.K., and Marnett,L.J. Trifluoromethyl fluorocoxib A detects cyclooxygenase-2 expression in inflammatory tissues and human tumor xenografts. ACS Medicinal Chemistry Letters, 2014, 5, 445-450 (*Corresponding Author), [Note – cover article]

28. Perrone, M. G., Malerba, P., Uddin, M. J., Vitale, P., Panella, A., Crews, B. C., Daniel, C. K.,  Ghebreselasie,K., Nickels, M., Tantawy, M. N., Manning, H. C., Marnett, L. J., Scilimati, A. PET radiotracer [18F]-P6 selectively targeting COX-1 as a novel biomarker in ovarian cancer: Preliminary investigation European Journal of Medicinal Chemistry 2014, 80, 562-568.

 

2013

27. Uddin, M. J., Crews, B. C., Ghebreselasie,K., and Marnett, L. J. Design, Synthesis, and Structure—Activity Relationship Studies of Fluorescent Inhibitors of Cycloxygenase-2 as Targeted Optical Imaging Agents. Bioconjugate Chemistry, 2013, 24, 712-723.

26. Blobaum, A.,* Uddin, M. J.,* Felts, A. S.; Crews, B. C.; Rouzer, C. A.; Marnett, L. J. The 2¢-trifluoromethyl analog of indomethacin as a potent and selective COX-2 inhibitor. ACS Medicinal Chemistry Letters, 2013, 4, 486-490. (*Joint 1st Author)

25. Cekanova, M., Uddin, M. J.; Bartges, J. W.; Callens, A.; Legendre, A. M.; Rathore, K.; Wright, L.; Carter, A.; Marnett, L. J. Molecular Imaging of Cyclooxygenase-2 in Canine Transitional Cell Carcinomas In Vitro and In Vivo by Fluorocoxib A. Cancer Prevention Research, 2013, 6, 466-476.

 

2012

24. Cekanova, M., Uddin, M. J.; Legendre, A. M.; Galyon, G.; Bartges, J. W.; Callens, A.; Martin-Jimenez, T.; Marnett, L. J. Single-dose safety and pharmacokinetic evaluation of Fluorocoxib A: pilot study of novel cyclooxygenase-2-targeted optical imaging agent in a canine model. Journal of Biomedical Optics, 2012, 17(11), 116002-116011.

23. Aldrich, M. B., Milton V. Marshall, M. V., Sevick-Muraca, E. M., Lanza, G., Kotyk, J., Joseph Culver, J., Wang, L. V., Uddin, M. J. et al. Seeing it through: translational validation of new medical imaging modalities. Biomecial Optics Express, 2012, 3(4), 764-776.

 

2011

22. Uddin, M. J., Crews, B. C., Ghebreselasie,K., Huda I., Kingsley, P. J., Ansari, M. S., Tantawy, M. N., Reese, J., and Marnett, L. J. Fluorinated COX-2 Inhibitors as Agents in PET Imaging of Inflammation and Cancer. Cancer Prevention Research, 2011, 4, 1536-1545. [Note – (i) cover article; (ii) ‘perspective on Uddin et al’; (iii) several newspaper headlines].

21. Uddin, M. J., Crews,B.C., Ghebreselasie,K., Tantawy, M. N., and Marnett,L.J. [123I]-Celecoxib Analogs as SPECT Tracer of Cyclooxygenase-2 (COX-2) in Inflammation. ACS Medicinal Chemistry Letters, 2010, 2, 160-164.

 

2010

20. Uddin, M. J., Schulte, M. I., Maddukuri, L., Harp, J., and Marnett, L. J. Semisynthesis of 6-Chloropurine-2′-deoxyriboside 5′-Dimethoxytrityl 3′-(2-cyanoethyl-N,N-diisopropylamino)phosphoramidite and its Use in the Synthesis of Fluorescently-Labeled Oligonucleotides. Nucleosides, Nucleotides and Nucleic Acids, 2010, 29, 831-840.

19. Uddin, M. J., Crews, B. C., Blobaum, A. L., Kingsley, P. J., Piston, D. W., Gordon, L., McIntyre, O., Matrisian, L., Dannenberg, A. J., Subbarahmiah, K., and Marnett, L. J. Selective visualization of Cyclooxygenase-2 in inflammation and cancer by targeted fluorescent imaging agents. Cancer Research, 2010, 70(9), 3618-3627. [Note – published with several newspaper headlines]

18. Uddin, MJ,  Smithson, DC, Brown, KM, Crews, BC, Connelly, M, Zhu, F, Marnett, LJ, Guy, RK. Podophyllotoxin analogues active versus Trypanosoma brucei. Bioorg Med Chem Lett, 2010, 20(5), 1787-1791.

 

2009

17. Uddin, M. J., Crews, B. C., Blobaum, A. L., Kingslay, P. J., Ghebraselase, K., Saleh, S. S., Clanton, J. A., Baldwin, R. M. and Marnett, L. J. Synthesis and evaluation of [123I]-indomethacin derivatives as COX-2 targeted imaging agents. Journal of Labelled Compounds and Radiopharmaceuticals, 2009, 52, 387-393.

16. Konkle, ME, Hargrove, TY, Kleshchenko, YY, von Kries, JP, Ridenour, W,  

Uddin, M.J., Caprioli, RM, Marnett, LJ, Nes, WD, Villalta, F, Waterman, MR, Lepesheva, GI. Indomethacin amides as a novel molecular scaffold for targeting Trypanosoma cruzi sterol 14alpha-demethylase. J Med Chem, 2009, 52(9), 2846-2853.

 

2008

15. Uddin, M. J., Marnett, LJ. Synthesis of 5- and 6-carboxy-X-rhodamines. Org Lett, 2008, 10(21), 4799-4801.

 

2006

14. Anning, P. B.; Coles, B; Morton, J.; Wang, H.; Uddin, M. J.; Morrow, J. D.; Dey, S. K.; Marnett, L. J.; Odonnell, V. B. Nitric oxide deficiency promotes vascular side effects of cyclooxygenase inhibitors. Blood, 2006, 13, 4059-4062.

 

2005

13. Uddin, M. J.; Rao, P. N. P.; McDonald, R.; Knaus, E. E.

Design and Synthesis of (E)-1,1,2-triarylethenes: Novel Inhibitors of the Cyclooxygenase-2 (COX-2) Isozyme. Bioorganic & Medicinal Chemistry Letters 2005, 15, 439-442.

12. Uddin, M. J.; Rao, P. N. P.; Knaus, E. E.

Design and Synthesis of (Z)-1,2-Diphenyl-1-(4-methanesulfonamidophenyl-2-alk-1-enes and (Z)-1-(4-azidophenyl)-1,2-diphenyl-2-alk-1-enes: Novel Inhibitors of Cyclooxygenase-2 (COX-2) with Antiinflammatory and Analgesic Activity. Bioorganic & Medicinal Chemistry 2005, 13, 417-424.

 

2004

11. Uddin, M. J.; Rao, P. N. P.; Knaus, E. E.

Design and Synthesis of Acyclic Triaryl (Z)-Olefins: A Novel Class of Cyclooxygenase-2 (COX-2) Inhibitors. Bioorganic & Medicinal Chemistry 2004, 12, 5929-5940.

10. Uddin, M. J.; Rao, P. N. P.; McDonald, R.; Knaus, E. E.

A New Class of Acyclic 2-alkyl-1,1,2-Triaryl (Z)-Olefins as Selective Cyclooxygenase-2 (COX-2) inhibitors. Journal of Medicinal Chemistry 2004, 47, 6108-6111.

9. Uddin, M. J.; Rao, P. N. P.; Rahim, M. A.; McDonald, R.; Knaus, E. E.

A New Class of Acyclic 2-alkyl-1,2-diaryl (E)-Olefins as Selective Cyclooxygenase-2 (COX-2) inhibitors. Bioorganic & Medicinal Chemistry Letters 2004, 14, 4911-4914.

8. Rao, P. N. P.; Uddin, M. J.; Knaus, E. E.

Design, Synthesis and Structure-Activity Relationship (SAR) Studies of 3,4,6-Triphenylpyran-2-ones as Selective Cyclooxygenase-2 (COX-2) Inhibitors. Journal of Medicinal Chemistry, 2004, 47, 3972-3990.

7. Uddin, M. J.; Rao, P. N. P.; Knaus, E. E.

Methylsulfonyl and Hydroxyl Substituents Induce (Z)-Stereocontrol in the McMurry Olefination Reaction. Synlett 2004, 9, 1513-1516.

6. Uddin, M. J.; Rao, P. N. P.; Knaus, E. E.

Design of Acyclic Triaryl Olefins: A New Class of Potent and Selective Cyclooxygenase-2 (COX-2) Inhibitors. Bioorganic & Medicinal Chemistry Letters 2004, 14, 1953-1956.

 

2003

5. Uddin, M. J.; Rao, P. N. P.; Knaus, E. E.

Design, Synthesis and Biological Evaluation of Novel Rofecoxib Analogs as Potential Cyclooxygenase-2 (COX-2) Inhibitors: Replacement of Methylsulfonyl Pharmacophore by a Sulfonylazide Bioisostre. Journal of Heterocyclic Chemistry 2003, 40, 861-868.

4. Uddin, M. J.; Rao, P. N. P.; Knaus, E. E.

Design, Synthesis and Biological Evaluation of Novel Celecoxib Analogs as Selective Cyclooxygenase-2 (COX-2) Inhibitors: Replacement of Sulfonamide Pharmacophore by a Sulfonylazide Bioisostre. Bioorganic & Medicinal Chemistry 2003, 11, 5273-5280.

 

2000

3. Uddin, M. J.; Shinooka, A.; Fujimoto, T.; Shirai, H.; Yamamoto, I.

Isoxazolidine Based New Chral Auxiliary for Asymmetric Synthesis. Heterocyclic Communications 2000, 6, 505-510

2. Uddin, M. J.; Fujimoto, T.; Kakehi, A.; Shirai, H.; Yamamoto, I.

Diastereoselective Synthesis of Bridgehead Heterocyclic Spiro Compounds Derived from Tandem Michael Intramolecular 1,3-Dipolar Cycloaddition of Nitrones. Heterocyclic Communications 2000, 6, 113-118

1. Uddin, M. J.; Kikuchi, M.; Takedatsu, K.; Arai, K.-I.; Fujimoto, T.; Motoyoshiya, J.; Kakehi, A.; Iriue, R.; Shirai, H.; Yamamoto, I. “Synthesis and Structure of Condensed Heterocycles Derived from Intramolecular 1,3-Dipolar Cycloaddition of Transient and Enantiomerically Pure a-Allylamino Nitrones and Nitrile Oxides in a High Level of Diastereoselectivity.” Synthesis 2000, 3, 365-374

 

 

SELECTED TALKS

21. Uddin, M. J., Crews, B. C., Uddin, M. I., Ghebreselasie, K., Daniel, C.K., Wilson, A. J., Nickels, M. L., Tantawy, M. N., Manning, H. C., Khalele, D., Marnett, L. J. “Targeted PET imaging of COX-1 in Ovarian Cancer.” World Molecular Imaging Congress, Honolulu HI 2015

20. Uddin, M. J., Crews, B. C., Uddin, M. I., Ghebreselasie, K., Daniel, C.K., Wilson, A. J., Nickels, M. L., Tantawy, M. N., Manning, H. C., Khalele, D., Marnett, L. J. “Targeted PET imaging of COX-1 in Ovarian Cancer.” Frontiers of Biomedical Imaging, VUIIS Nashville TN 2015

19. ORAL TALK - Uddin, M. J.; Brenda C. Crews; et al. “Flurocoxib C. A long-lived NIR COX-2 Probe enabling selective visualization of inflammation and cancer ” International Conference of Radiology and Imaging, Chicago, IL 2013

18. INVITED SPEAKER - Uddin, M. J.; Brenda C. Crews; et al. “A novel approach to biomolecular imaging of COX-2” AACR Frontiers in Cancer Research, Anaheim CA 2012

17. ORAL TALK - Uddin, M. J.; Brenda C. Crews; Marnett, L. J. “COX-2 inhibitors in PET imaging of inflammation and cancer” AACR-ACS Meeting – Chemistry in Cancer Research, San Diego CA 2011

16. Uddin, M. J.; Brenda C. Crews; Marnett, L. J.“Near-infrared fluorescence imaging of inflammation and cancer” NCI Translates, Washington DC  2011

15. Uddin, M. J.; Brenda C. Crews; Marnett, L. J.“18F-Labeled COX-2 inhibitors in PET imaging of inflammation and cancer ” Frontiers of Biomedical Imaging, VUIIS 2011

13. Uddin, M. J.; Brenda C. Crews; Marnett, L. J.“Rhodamine-based new fluorophores for imaging” 6th Vanderbilt Institute of Chemical Biology Retreat, Vanderbilt University, TN  2010

12. Uddin, M. J.; Crews, B. C.; Blobaum, A., Kingsley, P., Piston, D., Marnett, L. J.

“NASIDs in Cancer Detection” NCI Translates, VA  2009

11. ORAL TALK - Uddin, M. J.; Crews, B. C.; Marnett, L. J. “Cytostatic activity of NSAID-Podophylotoxin conjugates” 11th International Conference — Bioactive Lipids in Cancer, Inflammation and Related Diseases, Cancun, Mexico 2009

10. Uddin, M. J.; Brenda C. Crews; Marnett, L. J. “COX-2 targeted toxic agents” 5rd Vanderbilt Institute of Chemical Biology Retreat, Vanderbilt University, TN  2009

9. Uddin, M. J.; Brenda C. Crews; Marnett, L. J.“COX-2 targeted fluorescent Imaging agents” Frontiers of Biomedical Imaging, VUIIS 2008

8. Uddin, M. J.; Brenda C. Crews; Dannenberg, A. J., Subbarahmiah, K.; Marnett, L. J. “COX-2 targeted Imaging of Cancer” 6th AACR International Conference on Frontiers in Cancer Prevention Research, Philadelphia PA, 2007

7. Uddin, M. J.; Brenda C. Crews; Marnett, L. J.“COX-2 targeted Therapeutic Agents” 3rd Vanderbilt Institute of Chemical Biology Retreat, Vanderbilt University, TN  2007

6. Uddin, M. J.; Brenda C. Crews; Marnett, L. J. “COX-2 targeted Molecular Imaging Agents” 2nd Vanderbilt Institute of Chemical Biology Retreat, Vanderbilt University, TN  2006

5. Uddin, M. J.; Brenda C. Crews; Marnett, L. J. “Fluorescent Derivatives of Indomethacin as Selective Inhibitor of Cyclooxygenase-2.” U54 Network in Translational Research in Optical Imaging Retreat, Stanford University, California 2005

4. ORAL TALK -  Uddin, M. J.; Rao, P. N. P.; Knaus, E. E. “Design of Selective Cyclooxygenase-2 Inhibitors.” Drug Discovery 2004 Lecture Series, University of Alberta Canada 2004

3. Uddin, M. J.; Rao, P. N. P.; Knaus, E. E.“Design and Synthesis of Acyclic Triaryl Olefins: A New Class of Highly Potent and Selective Cyclooxygenase-2 (COX-2) Inhibitors.” 12th Symposium on Organo-Metallic Chemistry Directed Toward Organic Synthesis (OMCOS 12), Toronto University, Toronto, Canada 2003

2. Uddin, M. J.; Rao, P. N. P.; Knaus, E. E. “Design, Synthesis and Biological Evaluation of Novel Celecoxib and Rofecoxib Analogs as Selective Cyclooxygenase-2 (COX-2) Inhibitors: Replacement of Sulfonamide and Methylsulfonyl Pharmacophore by a Sulfonylazide Bioisostre.” 5th Annual Symposium of Canadian Society for Pharmaceutical Sciences, Banff Center, Alberta, Canada 2002

1. ORAL TALK - Uddin, M. J.; Kikuchi, M.; Takedatsu, K.; Arai, K.-I.; Fujimoto, T.; Yamamoto, I. “Synthesis of Isoxazolidine fused Heterocycles from Diastereoselective Intramolecular 1,3-Dipolar Cycloaddition of Nitrones.” 76th Annual Meeting of the Chemical Society of Japan, Kanagawa, Japan 1999